Cargando…
Antimicrobial peptides with selective antitumor mechanisms: prospect for anticancer applications
In the last several decades, there have been significant advances in anticancer therapy. However, the development of resistance to cancer drugs and the lack of specificity related to actively dividing cells leading to toxic side effects have undermined these achievements. As a result, there is consi...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5542299/ https://www.ncbi.nlm.nih.gov/pubmed/28422728 http://dx.doi.org/10.18632/oncotarget.16743 |
_version_ | 1783254963867090944 |
---|---|
author | Deslouches, Berthony Di, Y. Peter |
author_facet | Deslouches, Berthony Di, Y. Peter |
author_sort | Deslouches, Berthony |
collection | PubMed |
description | In the last several decades, there have been significant advances in anticancer therapy. However, the development of resistance to cancer drugs and the lack of specificity related to actively dividing cells leading to toxic side effects have undermined these achievements. As a result, there is considerable interest in alternative drugs with novel antitumor mechanisms. In addition to the recent approach using immunotherapy, an effective but much cheaper therapeutic option of pharmaceutical drugs would still provide the best choice for cancer patients as the first line treatment. Ribosomally synthesized cationic antimicrobial peptides (AMPs) or host defense peptides (HDP) display broad-spectrum activity against bacteria based on electrostatic interactions with negatively charged lipids on the bacterial surface. Because of increased proportions of phosphatidylserine (negatively charged) on the surface of cancer cells compared to normal cells, cationic amphipathic peptides could be an effective source of anticancer agents that are both selective and refractory to current resistance mechanisms. We reviewed herein the prospect for AMP application to cancer treatment, with a focus on modes of action of cationic AMPs. |
format | Online Article Text |
id | pubmed-5542299 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-55422992017-08-07 Antimicrobial peptides with selective antitumor mechanisms: prospect for anticancer applications Deslouches, Berthony Di, Y. Peter Oncotarget Review In the last several decades, there have been significant advances in anticancer therapy. However, the development of resistance to cancer drugs and the lack of specificity related to actively dividing cells leading to toxic side effects have undermined these achievements. As a result, there is considerable interest in alternative drugs with novel antitumor mechanisms. In addition to the recent approach using immunotherapy, an effective but much cheaper therapeutic option of pharmaceutical drugs would still provide the best choice for cancer patients as the first line treatment. Ribosomally synthesized cationic antimicrobial peptides (AMPs) or host defense peptides (HDP) display broad-spectrum activity against bacteria based on electrostatic interactions with negatively charged lipids on the bacterial surface. Because of increased proportions of phosphatidylserine (negatively charged) on the surface of cancer cells compared to normal cells, cationic amphipathic peptides could be an effective source of anticancer agents that are both selective and refractory to current resistance mechanisms. We reviewed herein the prospect for AMP application to cancer treatment, with a focus on modes of action of cationic AMPs. Impact Journals LLC 2017-03-31 /pmc/articles/PMC5542299/ /pubmed/28422728 http://dx.doi.org/10.18632/oncotarget.16743 Text en Copyright: © 2017 Deslouches and Di http://creativecommons.org/licenses/by/3.0/ This article is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) (CC-BY), which permits unrestricted use and redistribution provided that the original author and source are credited. |
spellingShingle | Review Deslouches, Berthony Di, Y. Peter Antimicrobial peptides with selective antitumor mechanisms: prospect for anticancer applications |
title | Antimicrobial peptides with selective antitumor mechanisms: prospect for anticancer applications |
title_full | Antimicrobial peptides with selective antitumor mechanisms: prospect for anticancer applications |
title_fullStr | Antimicrobial peptides with selective antitumor mechanisms: prospect for anticancer applications |
title_full_unstemmed | Antimicrobial peptides with selective antitumor mechanisms: prospect for anticancer applications |
title_short | Antimicrobial peptides with selective antitumor mechanisms: prospect for anticancer applications |
title_sort | antimicrobial peptides with selective antitumor mechanisms: prospect for anticancer applications |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5542299/ https://www.ncbi.nlm.nih.gov/pubmed/28422728 http://dx.doi.org/10.18632/oncotarget.16743 |
work_keys_str_mv | AT deslouchesberthony antimicrobialpeptideswithselectiveantitumormechanismsprospectforanticancerapplications AT diypeter antimicrobialpeptideswithselectiveantitumormechanismsprospectforanticancerapplications |